InsermU999
@InsermU999
Followers
56
Following
136
Media
3
Statuses
103
Happy to share our latest publication from the fruitful collaboration between @InsermU999 & @Umr1180! "Ca2+ Cycling Alteration in a Porcine Model of Right Ventricular Dysfunction" Circulation Heart Failure @pulmotension @SPLF_SocPneumo @HTaPFrance
https://t.co/nV0qVW3hHs
0
2
3
Happy to share our latest collaborative work: "Approach to Lung Transplantation in #PAH: A Delphi Consensus" just published online in Pulmonary Circulation @SavaleL @pulmotension @SPLF_SocPneumo @InsermU999 @HTaPFrance
https://t.co/6uqniX7qwQ
0
12
26
Thanks to the journal Chest #JournalCHEST for highlighting our article on the association between trastuzumab emtansine and pulmonary arterial hypertension #PAH
https://t.co/mrAekds42P
@SPLF_SocPneumo @HTaPFrance
@InsermU999 @pulmotension
INSIDE LOOK 👀 Read more of the latest research from the upcoming issue (May 8): Is there an association between trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan and the development of #PAH? Read the full research: https://t.co/f1Iz2eAd8y
#MedEd #JournalCHEST
0
5
13
Proud to share our new publication in Respiratory Medicine and Research 'PAH-approved drugs in PH associated with COPD: a systematic literature review.' Grateful to my co-authors ! @SPLF_SocPneumo
@pulmotension @SPLF_SocPneumo @InsermU999
https://t.co/C1pyvH8y0u
1
19
68
Phenotyping PH in COPD is a major challenge in respiratory medicine. Grateful for the great collaboration with the Strasbourg team. Our study is now out in ERJ Open Research @pulmotension
@InsermU999
@SPLF_SocPneumo
@HTaPFrance
https://t.co/RXKom4z1CC
1
16
40
A key contribution on a major topic "Initial therapy in patients with #PAH and cardiovascular comorbidities" just published in @ERSpublications Thanks to @AthenaisBoucly @SavaleL and the @pulmotension network @SPLF_SocPneumo
https://t.co/XWvKesa3Mj
0
16
22
#JRF-HTP @OSitbon @Montanidavid @AthenaisBoucly @jeanlucvachiery @madelcroix @OrphaLung @RespiFIL @pulmotension @Hopital_Bicetre @UnivParisSaclay
Franc succès des Journées du Réseau Français #Hypertension #Pulmonaire des 17 et 18 octobre 2024 au CHU de Bicêtre , centre national de référence Avec 267 participants à l’auditorium du bâtiment recherche
0
3
13
Deeply concerning to receive #PAH study proposals from Akros Pharma, a pharmaceutical company emerging from Japan Tobacco Inc. The tobacco industry, responsible for 8 million deaths annually, has no place in medical research funding. @SPLF_SocPneumo @EuroRespSoc @pulmotension
4
4
21
Happy to share our recent collaboration published in Rheumatology : "Anti-fibroblast and anti-endothelial cell autoantibodies in SLE- and MCTD-PAH" @ThoreauBenjamin @pulmotension @InsermU999 @SPLF_SocPneumo
https://t.co/yVkuoFknTA
2
4
14
Welcome to Grégoire Ruffenach to the Research Unit @InsermU999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies". Just arrived, and already full of projects and opportunities. Happy to have you on the team. @pulmotension @HTaPFrance @SPLF_SocPneumo
2
1
10
Professor Humbert sharing updates from the 7th WSPH @DeBakeyCVedu @HMHCardioFellow @HMHpccm @EuropePHA @teamphhope @PHAssociation @ATS_PC @CHESTPulmCardio One of the most important slides!!
0
2
13
Amazing learning experience, discussions on PH, career mentoring, academic growth, food and fun over the last couple of days! @EuropePHA @ATS_PC @PHAssociation @HMHCardioFellow @HMethodistMD
Feeling inspired by Professor Humbert’s lectures this past week 🤩 ✔️Weigh PAH & comorbidities in Rx ✔️Progress in genetic & pathobiology ➡️ sotatercept! ✔️Future research to improve upon current median survival of 7 yrs Thank you @SandeepSahayMD for hosting & inviting me! #PH
0
2
14
The "DELPHI-2 Study" journey continue with our latest publication in Chest: "Role of Exercise Hemodynamics in the Prediction of #PAH in BMPR2 Mutation Carriers" @pulmotension @SPLF_SocPneumo @InsermU999 @HTaPFrance @ChristianGerges @BogaardHarm
https://t.co/IfN5Otr967
0
7
23
Happy to share this recent review "Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH" published in Blood Reviews @pulmotension @LaurentBertole1 @InsermU999 @HTaPFrance @SPLF_SocPneumo
https://t.co/tKe7ECOEdG
1
9
29
Élise Noël-Savina @CHUdeToulouse décrit les impacts des ces réévaluations pour le #diagnostic, les #cliniciens et aussi qui sont ces #patients.
0
3
6
🔴 J1 [JRF-HTP] : session 2 - @Montanidavid intervient sur la réévaluation de la définition, la classification et le diagnostic de l’HTP par rapport aux guidelines @EuroRespSoc @ESC_Journals 2022 : déf. conservée, classe 3 modifiée avec des maladies. 🗞 https://t.co/4A1GntUBeV
1
3
11
🔴 J2 [JRF-HTP] : session 5 - Marion Delcroix @UZLeuven présente les conclusions du #WSPH 2024 pour le traitement de l'#HTP thrombo-embolique chronique : #endartériectomie / l'#angioplastie pulmonaire et thérapie médicale ciblée HTP. 🗞 https://t.co/jjmfygl4aS
#CTEPH #PEA #BEA
1
3
7
The Blue Journal thanks Fabien Robert, PharmD, MSc, for his contribution to the September 1 issue Disrupted BMP-9 Signaling Impairs Pulmonary Vascular Integrity in Hepatopulmonary Syndrome https://t.co/qZ72VtJAvL
0
5
10
#J2R : 200 participants , un superbe comité d'organisation et un joli programme sur 2 jours #Recherche #Respiratoire #Pneumologie
1
6
15
Le congrès des J2R de la SPLF. Un énorme succès à Paris dans un lieu magnifique et de la recherche de haute volée. Bravo à tous les laboratoires de recherche en pneumologie 🫁👏 👉 https://t.co/JQNg8ogcQW
2
6
22